тромбозопухольгепаринVEGF1.1. Trousseau A. Phlegmasia alba dolens. In: A. Trousseau (ed). Clinique medicale de l'Hotel-Dieu de Paris. Paris, BaillШre; 1865. p. 654-712.Trousseau A. Phlegmasia alba dolens. In: A. Trousseau (ed). Clinique medicale de l'Hotel-Dieu de Paris. Paris, BaillШre; 1865. p. 654-712.2.2. Kakkar A.K., DeRuvo H., Chinswanqtanakul V. et al. Extrinsicpathway activation in cancer with high factor Vila and tissue factor. Lancet 1995;346(8981):1004-5.Kakkar A.K., DeRuvo H., Chinswanqtanakul V. et al. Extrinsicpathway activation in cancer with high factor Vila and tissue factor. Lancet 1995;346(8981):1004-5.3.3. Kakkar A.K., Chinswangwatanakul V., Tebbutt S. et al. A characterization of the coagulant and fibrinolytic profile of human pancreatic carcinoma cells. Haemostasis 1998;28:1-6.Kakkar A.K., Chinswangwatanakul V., Tebbutt S. et al. A characterization of the coagulant and fibrinolytic profile of human pancreatic carcinoma cells. Haemostasis 1998;28:1-6.4.4. Luzzato G., Schafer A.L. The prethrombotic state in cancer. Semin Oncol 1990;17:147-59.Luzzato G., Schafer A.L. The prethrombotic state in cancer. Semin Oncol 1990;17:147-59.5.5. Francis J.L. Haemostasis and cancer. Med Lab Sci 1989;46:331-46.Francis J.L. Haemostasis and cancer. Med Lab Sci 1989;46:331-46.6.6. Decensi A., Maisonneuve P., Rotmensz N. et al. Effect of tamoxifen on venous trom-boembolic events in a breast cancer prevention. Circulation 2005;111(5):650-6.Decensi A., Maisonneuve P., Rotmensz N. et al. Effect of tamoxifen on venous trom-boembolic events in a breast cancer prevention. Circulation 2005;111(5):650-6.7.7. Sorensen H.T., Mellemkjaer L., Olsen J.H. et al. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000;343:1846-50.Sorensen H.T., Mellemkjaer L., Olsen J.H. et al. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000;343:1846-50.8.8. Beer J.H., Haeberli A., Vogt A. et al. Coagulation markers predict survival in cancer patients. Thromb Haemost 2002;88:745-9.Beer J.H., Haeberli A., Vogt A. et al. Coagulation markers predict survival in cancer patients. Thromb Haemost 2002;88:745-9.9.9. Miller G.J., Bauer K.A., Howarth D.J. et al. Increased incidence of neoplasia of the digestive tract in men with persistent activation of the coagulant pathway. J Thromb Haemost 2004;2:2107-14.Miller G.J., Bauer K.A., Howarth D.J. et al. Increased incidence of neoplasia of the digestive tract in men with persistent activation of the coagulant pathway. J Thromb Haemost 2004;2:2107-14.10.10. Green D., Hull R.D., Brant R., Pineo G.F. Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin. Lancet 1992; 339:1476.Green D., Hull R.D., Brant R., Pineo G.F. Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin. Lancet 1992; 339:1476.11.11. Ginsberg J.S. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a metaanalysis. Am J Med 1996;100:269-77.Ginsberg J.S. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a metaanalysis. Am J Med 1996;100:269-77.12.12. Zacharski L.R., Ornstein D.L., Mamourian A.C. Low-molecularweight heparin and cancer. Sem Thromb Hemost 2000;26(Suppl 1):69-77.Zacharski L.R., Ornstein D.L., Mamourian A.C. Low-molecularweight heparin and cancer. Sem Thromb Hemost 2000;26(Suppl 1):69-77.13.13. Bobek V., Kovarik J. Antitumor and antimetastatic effect of warfarin and heparins. Biomed Pharmacother 2004;58:213-9.Bobek V., Kovarik J. Antitumor and antimetastatic effect of warfarin and heparins. Biomed Pharmacother 2004;58:213-9.14.14. Wang A., Templeton D.M. Inhibition of mitogenesis and c-fos induction in mesangial cells by heparin and heparan sulfates. Kidney Int 1996;49(2):437-48.Wang A., Templeton D.M. Inhibition of mitogenesis and c-fos induction in mesangial cells by heparin and heparan sulfates. Kidney Int 1996;49(2):437-48.15.15. Folkman J., Weisz P.B., Joullie M.M. et al. Control of angiogenesis with synthetic heparin substitutes. Science 1989;243:1490-3.Folkman J., Weisz P.B., Joullie M.M. et al. Control of angiogenesis with synthetic heparin substitutes. Science 1989;243:1490-3.16.16. Collen A., Koolwijk P., Kroon M.E., van Hinsbergh V.W.M. The influence of fibrin structure on the formation and maintenance of capillary-like tubules. Angiogenesis 1998;2:153-65.Collen A., Koolwijk P., Kroon M.E., van Hinsbergh V.W.M. The influence of fibrin structure on the formation and maintenance of capillary-like tubules. Angiogenesis 1998;2:153-65.17.17. Mousa S.A., Mohamed S. Inhibition of endothelial cell tube formation by the low molecular weight heparin, tinzaparin, is mediated by tissue factor pathway inhibitor. Thromb Haemost 2004;92:627-33.Mousa S.A., Mohamed S. Inhibition of endothelial cell tube formation by the low molecular weight heparin, tinzaparin, is mediated by tissue factor pathway inhibitor. Thromb Haemost 2004;92:627-33.18.18. Wahrenbrock M., Borsig L., Le D. et al. Selectin-mucin interactions as a probable molecular explanation for the association of Trousseau syndrome with mucinous adenocarcinomas J Clin Invest 2003;112(6): 853-62.Wahrenbrock M., Borsig L., Le D. et al. Selectin-mucin interactions as a probable molecular explanation for the association of Trousseau syndrome with mucinous adenocarcinomas J Clin Invest 2003;112(6): 853-62.19.19. Biggerstaff J.P., Seth N., Amirkhosravi A. et al. Soluble fibrin augments platelet/tumor cell adherence in vitro and in vivo and enhances experimental metastasis. Clin Exp Metastasis 1999;17:723-90.Biggerstaff J.P., Seth N., Amirkhosravi A. et al. Soluble fibrin augments platelet/tumor cell adherence in vitro and in vivo and enhances experimental metastasis. Clin Exp Metastasis 1999;17:723-90.20.20. Clifton E.E., Agostino D. Factors affecting the development of metastatic cancer. Cancer 1962;15:276-83.Clifton E.E., Agostino D. Factors affecting the development of metastatic cancer. Cancer 1962;15:276-83.21.21. Lee A.E., Rogers L.A., Jeffery R.E., Longcroft J.M. Comparison of metastatic cell lines derived from a murine mammary tumour, and reduction of metastasis by heparin. Clin Exp Metastasis 1988;6:463-71.Lee A.E., Rogers L.A., Jeffery R.E., Longcroft J.M. Comparison of metastatic cell lines derived from a murine mammary tumour, and reduction of metastasis by heparin. Clin Exp Metastasis 1988;6:463-71.22.22. Angelini A., Di Febbo C., Ciofani G. et al. Inhibition of P-Glycoprotein-medi-ated multidrug resistance by unfractionated heparin: a new potential chemosensi-tizer for cancer therapy. Cancer Biol Ther 2005;4:313-7.Angelini A., Di Febbo C., Ciofani G. et al. Inhibition of P-Glycoprotein-medi-ated multidrug resistance by unfractionated heparin: a new potential chemosensi-tizer for cancer therapy. Cancer Biol Ther 2005;4:313-7.23.23. Ghosh B.C., Cliffton E.E. Malignant tumors with superior vena cava obstruction. N Y State J Med 1973;73:283-9.Ghosh B.C., Cliffton E.E. Malignant tumors with superior vena cava obstruction. N Y State J Med 1973;73:283-9.24.24. Lebeau B., Chastang C.L., Brechot J.M. Subcutaneous heparin treatment increases complete response rate and overall survival in small cell lung cancer. Lung Cancer 1991;7 (Suppl):129-34.Lebeau B., Chastang C.L., Brechot J.M. Subcutaneous heparin treatment increases complete response rate and overall survival in small cell lung cancer. Lung Cancer 1991;7 (Suppl):129-34.25.25. Prandoni P., Lensing A.W., Buller H.R. et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 1992;339(8791):441-5.Prandoni P., Lensing A.W., Buller H.R. et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 1992;339(8791):441-5.26.26. Hettiarachchi R.J., Smorenburg S.M., Ginsberg J. Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread.Thromb Haemost 1999;82(2):947-52.Hettiarachchi R.J., Smorenburg S.M., Ginsberg J. Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread.Thromb Haemost 1999;82(2):947-52.27.27. Gould M., Dembitzer A.D., Doyle R.L. et al. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann Intern Med 1999;130:800-9.Gould M., Dembitzer A.D., Doyle R.L. et al. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann Intern Med 1999;130:800-9.28.28. Hirsh J., Warkentin T.E., Shaughnessy S.G. et al. Heparin and low-molecular-weight heparin mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001;119(Suppl):64S-94S.Hirsh J., Warkentin T.E., Shaughnessy S.G. et al. Heparin and low-molecular-weight heparin mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001;119(Suppl):64S-94S.29.29. Khorana A.A., Sahni A., Altland O.B. et al. Heparin inhibition of endothelial cell proliferation and organization is dependent on molecular weight arteriosclerosis, thrombosis, and vascular biology. 2003;23(11):2110-5.Khorana A.A., Sahni A., Altland O.B. et al. Heparin inhibition of endothelial cell proliferation and organization is dependent on molecular weight arteriosclerosis, thrombosis, and vascular biology. 2003;23(11):2110-5.30.30. Collen A., Smorenburg M., Peters E. Unfractionated and low molecular weight heparin affect fibrin structure and angiogenesis in vitro. Cancer Res 2000;60:6196-200.Collen A., Smorenburg M., Peters E. Unfractionated and low molecular weight heparin affect fibrin structure and angiogenesis in vitro. Cancer Res 2000;60:6196-200.31.31. Castelli R., Porro F., Tarsia P. The heparins and cancer: review of clinical trials and biological properties. Vasc Med 2004;9(3):205-13.Castelli R., Porro F., Tarsia P. The heparins and cancer: review of clinical trials and biological properties. Vasc Med 2004;9(3):205-13.32.32. Lee A.Y.Y., Levine M.N., Baker R.I. et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349:146-53.Lee A.Y.Y., Levine M.N., Baker R.I. et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349:146-53.33.33. Lee A.Y.Y., Rickles F.R., Julian J.A. et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 2005;23:2123-9.Lee A.Y.Y., Rickles F.R., Julian J.A. et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 2005;23:2123-9.34.34. Kakkar A.K., Levine M.N., Kadziola Z. et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the Fragmin Advanced Malignancy Outcome Study (FAMOUS). J Clin Oncol 2004;22:1944-8.Kakkar A.K., Levine M.N., Kadziola Z. et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the Fragmin Advanced Malignancy Outcome Study (FAMOUS). J Clin Oncol 2004;22:1944-8.35.35. Klerk C.P.W., Smorenburg S.M., Otten H.M. et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005;23:2130-5.Klerk C.P.W., Smorenburg S.M., Otten H.M. et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005;23:2130-5.36.36. Sideras K., Shaefer P.L., Okuno S.H. et al. Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clinic Proc 2006;81(6):758-67.Sideras K., Shaefer P.L., Okuno S.H. et al. Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clinic Proc 2006;81(6):758-67.37.37. Altinbas M., Coskun H.S., Er O. et al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2004;2:1-6.Altinbas M., Coskun H.S., Er O. et al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2004;2:1-6.38.38. Schulman S., Lindmarker P. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism: duration of anticoagulation trial. N Engl J Med 2000;342:1953-8.Schulman S., Lindmarker P. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism: duration of anticoagulation trial. N Engl J Med 2000;342:1953-8.39.39. Geerts W.H., Pineo G.F., Heit J.A. et al. Prevention of venous thromboembolism. The Seventh ACCP Consensus Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 Suppl):338S-400S.Geerts W.H., Pineo G.F., Heit J.A. et al. Prevention of venous thromboembolism. The Seventh ACCP Consensus Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 Suppl):338S-400S.40.40. Buller H.R., Agnelli G., Hull R.D. et al. Antithrombotic therapy for venous thromboembolic disease. The Seventh ACCP Consensus Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 Suppl):401S-428S.Buller H.R., Agnelli G., Hull R.D. et al. Antithrombotic therapy for venous thromboembolic disease. The Seventh ACCP Consensus Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 Suppl):401S-428S.